101084-51-9 Usage
Description
6-Benzothiazolecarboxamide(6CI) is an organic compound with the molecular formula C7H6N2OS. It is a derivative of benzothiazole, a heterocyclic compound consisting of a benzene ring fused to a thiazole ring. 6-Benzothiazolecarboxamide(6CI) is known for its potential applications in various industries due to its unique chemical properties.
Uses
Used in Pharmaceutical Industry:
6-Benzothiazolecarboxamide(6CI) is used as a reactant for the synthesis of benzothiazolyl pyridyl alkanols, which are compounds with potential therapeutic applications. These synthesized compounds are particularly useful in treating conditions characterized by elevated levels of aldosterone, a hormone produced by the adrenal glands that regulates blood pressure and electrolyte balance. Additionally, benzothiazolyl pyridyl alkanols can be employed in the treatment of abnormal or excessive fibrosis, a condition where connective tissue accumulates abnormally in an organ or tissue, leading to impaired function.
Check Digit Verification of cas no
The CAS Registry Mumber 101084-51-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,0,8 and 4 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 101084-51:
(8*1)+(7*0)+(6*1)+(5*0)+(4*8)+(3*4)+(2*5)+(1*1)=69
69 % 10 = 9
So 101084-51-9 is a valid CAS Registry Number.
101084-51-9Relevant articles and documents
Synthesis and evaluation of 2-pyridylbenzothiazole, 2-pyridylbenzoxazole and 2-pyridylbenzofuran derivatives as 11C-PET imaging agents for β-amyloid plaques
Swahn, Britt-Marie,Wensbo, David,Sandell, Johan,Sohn, Daniel,Slivo, Can,Pyring, David,Malmstr?m, Jonas,Arzel, Erwan,Vallin, Michaela,Bergh, Margareta,Jeppsson, Fredrik,Johnson, Allan E.,Juréus, Anders,Neelissen, Jan,Svensson, Samuel
scheme or table, p. 1976 - 1980 (2010/07/07)
The syntheses and SAR of new series of β-amyloid binding agents are reported. The effort to optimize signal-to-background ratios for these ligands are described. Compounds 8, 21 and 30 displayed desirable lipophilicity and pharmacokinetic properties. Compounds 8 and 21 were evaluated with in vitro autoradiographic studies and in vivo in APP/PS1 transgenic mice. It is shown that it was possible to increase the signal-to-background ratios compared to PIB 1, as demonstrated by compounds 8 and 21.